This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data
Learn about funding and reimbursement for England, Scotland, Wales and Northern Ireland
Scroll through our resources about acromegaly management, patient resources, and experience with acromegaly
Menu
Close
Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data
Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Somavert works on cell surfaces around the body, directly targeting and blocking growth hormone receptors to inhibit IGF-I production with a high predictibility1-3
Study design: 12-week, randomised, double-blind study of three different doses of pegvisomant (10mg, 15mg, and 20mg) and placebo, given subcutaneously daily, in 112 patients with acromegaly. All patients had previously been treated with surgery, radiation therapy and/or medical therapies. 4
Baseline and lowest values of individual serum IGF-1 concentrations achieved in 90 patients treated for 12 months or more with daily injections.3
The shaded area represents age adjusted normal range for IGF-1
Study design: Prospective, open-label, 18-month, multicentre extension study that assessed the effects of Somavert in 160 patents with acromegaly treated for an everage of 425 days. 3
*Van der Lely 20013: 87/90 patients taking pegvisomant for 12 months or more.
100/108 (92.6%) of patients with available IGF-1 data had a normal IGF-1 concentration at any visit during pegvisomant treatment. 2/100 patients with normalised IGF-1 were administered doses of >30mg/day5.
The maximum licensed dose of Somavert should not exceed 30mg per day. Please refer to the Summary of Product Characteristics before prescribing Somavert1.
Somavert’s tumour-independent mechanism of action may explain how it can achieve IGF-1 normalisation rates of up to 97% when appropriately titrated (n=87/90)
Study Design: Observational multicentre surveillance study using the Patients-assessed Acromegaly Symptoms Questionnaire (PASQ) to evaluate signs and symptoms of acromegaly. Answers are scored based on 0 (no symptoms) to 8 (severe, incapacitating symptoms), or 0 (best possible health status) to 10 (worst possible health status).6
*Schreiber 20176:Of the 229 patients in the study, 94.1% of patients received doses between 10 and 30mg/day. Five patients had 10mg every second day; 6 patients recieved more than 30mg/day. 6
The maximum recommended dose of Somavert is 30mg/day. Please refer to the Summary of Product Characteristics before prescribing'.1
Patients on Somavert report significant reductions versus baseline in soft tissue swelling, headache, joint pain and general physical condition, and total signs and symptoms score‡1,6
‡Total signs and symptoms score reduction observed at 12 weeks (p<0.05, n=112).
To find out more about supporting your patients or to order starter kits.
Help find your patient's personal optimum by titrating doses
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024